Status:
COMPLETED
Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Schizophrenia
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Open label extension study of Ziprasidone, evaluation of safety of long term use of ziprasidone
Eligibility Criteria
Inclusion
- Patients who successfully completed study A1281031 (CGI score of 1 or 2 at final visit) or ZIP-NY-98035 and with QTc \<= 500 msec.
Exclusion
- All other patients who do not fit the inclusion criteria as stated above.
Key Trial Info
Start Date :
October 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT00174447
Start Date
October 1 2001
End Date
October 1 2008
Last Update
March 24 2021
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Avignon, France, 84000
2
Pfizer Investigational Site
DOLE Saint YLIE, France, 39108
3
Pfizer Investigational Site
Liévin, France, 62800
4
Pfizer Investigational Site
Lyon, France, 69373